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Lequesne Index (LI) ≥7 and pain ≥40mm on a visual analogical scale
(VAS). LI and VAS were assessed after 30, 60 and 91 days. Global efﬁcacy
evaluation and general product tolerability was also performed.
Results: Results were conﬁrmed both in per protocol (PP) and intend to
treat (ITT) population.
Non-inferiority was demonstrated after 3 month treatment between the
oral daily single dose of CS 1200 formulation and the 3 daily capsules of
CS 400 (delta = 0.13, [−0.81;1.08]).
Patients treated with CS 1200 or CS 3*400 were signiﬁcantly improved
compared to placebo in terms of LI (p < 0.0001).
LI score of patients treated with Chondrosulf® was signiﬁcantly improved
in both groups of CS4&6 at D60 and D91 (p< 0.01 and <0.001
respectively).
Pain scores were signiﬁcantly improved in both treatment groups at D91
(p =0.0052) compared to baseline and placebo.
The global efﬁcacy evaluation by patients and investigators showed a
statistically signiﬁcant superiority of both CS 1200 and CS 400 groups
compared to placebo after 60 and 91 days.
No signiﬁcant difference in terms of tolerance and tolerability was
observed between the 3 groups.
No serious AE were reported. No AE were related to study drug.
Conclusion: This study suggests that daily administration of an oral
sachet of 1200mg of chondroitin 4&6 sulfate (Chondrosulf®) allows a
signiﬁcant clinical improvement compared to placebo. A similar clinical
improvement was observed between the oral daily single dose of CS 1200
formulation and the 3 daily capsules of CS 400. No signiﬁcant difference
in tolerance and tolerability was observed across the two chondroitin
sulphate groups as compared to placebo.
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Purpose: Currently, there are no disease-modifying therapeutic strategies
for osteoarthritis (OA), a degenerative joint disease projected to
afﬂict more than 67 million Americans by 2030. In OA, the cells
responsible for maintenance of joint cartilage, articular chondrocytes
(AC) inappropriately undergo a maturational program normally only
associated with endochondral ossiﬁcation. Therefore, signaling pathways
that govern chondrocyte maturation represent candidate therapeutic
targets. Parathyroid hormone (PTH) induces chondrocyte matrix
synthesis and suppresses maturation via the PTH receptor 1 (PTHR1),
which we found to be up-regulated in ACs following meniscal injury and
during OA in humans and in injury-induced knee OA in mice. Thus,
we hypothesized that recombinant human PTH(1–34) (teriparatide)
would inhibit aberrant chondrocyte maturation and associated articular
cartilage degeneration.
Methods: PTHR1 levels were analyzed in injured and arthritic human
and mouse cartilage samples via immunograding and qPCR. We
administered systemic teriparatide, an FDA-approved treatment for
osteoporosis (Forteo), either immediately or beginning 8 weeks after
meniscal/ligamentous injury (MLI) in mice. Knee joints were harvested
at 4, 8, or 12 weeks post-MLI to examine the effects of teriparatide
on OA bone and cartilage phenotypes using microCT, histologic scoring,
morphometric methods and immunostaining. Bone phenotypes assessed
included subchondral bone volume and osteophyte formation. Cartilage
phenotypes examined included articular cartilage integrity and area, as
well as molecular assessment of AC maturation.
Results: Human cartilage samples harvested from non-OA patients
undergoing meniscal repair surgery or end-stage OA patients undergoing
total knee arthroplasty displayed increased PTHR1 levels as assessed
by immunostaining. Similarly, mice with progressing OA induced
by MLI surgery displayed increased PTHR1 levels as determined
by immunostaining and qPCR. Micro-computed tomography revealed
increased bone volume in knee joints following MLI. Teriparatide
treatment increased bone volume in both sham-operated and MLI
joints, conﬁrming the bone anabolic effect of the systemic therapy.
However, osteophyte formation initiated by MLI surgery was not
exacerbated by teriparatide treatment and no osteophytes were evident
in sham-operated joints from teriparatide-treated mice. Furthermore,
targeted activation of the PTHR1 in ACs by systemic teriparatide
treatment was demonstrated by increased expression of Jagged-1, a
direct transcriptional target of the receptor’s downstream signaling
pathway. Immediate systemic administration of teriparatide increased
proteoglycan abundance and decelerated articular cartilage degeneration.
Strikingly, delayed teriparatide treatment beginning 8 weeks post-injury
induced a chondro-regenerative effect. Overall, these effects correlated
with up-regulation of proteoglycan-4 and decreased levels of matrix
metalloproteinase-13, type X collagen and Runx2 in ACs.
Conclusions: These preclinical ﬁndings provide proof-of-concept for the
use of teriparatide (Forteo) to decelerate cartilage degeneration in OA
patients and to delay the onset of morbidity associated with end-stage
disease.
